

COCA Call Information

- ❑ For the best quality audio, we encourage you to use your computer's audio:
- ❑ Please click the link below to join the webinar:
- ❑ If you cannot join through digital audio, you may join by phone in listen-only mode:
- ❑ US: +1 646 876 9923 or +1 669 900 6833
- ❑ Webinar ID: 776 086 935
- ❑ All questions for the Q&A portion must be submitted through the webinar system.
- ❑ Please select the **Q&A button** at the bottom of the webinar, and enter your questions there.

Travel-associated Rickettsioses Guidance: Pre-travel Counseling, Diagnosis, Treatment, and Reporting

Clinician Outreach and Communication Activity (COCA)

May 7, 2019



Continuing Education for this COCA Call

All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and AAVSB/RACE) for COCA Calls are issued online through the [CDC Training & Continuing Education Online system](http://www.cdc.gov/TCEOnline/) (<http://www.cdc.gov/TCEOnline/>).

Those who participated in today's COCA Call and who wish to receive continuing education should complete the online evaluation by **June 10, 2019** with the course code **WC2922**.

Those who will participate in the on demand activity and wish to receive continuing education should complete the online evaluation between **June 10, 2019** and **June 10, 2021** will use course code **WD2922**.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE's obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

Continuing Education Disclaimer

- ❑ In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
- ❑ Planners have reviewed content to ensure there is no bias. Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
- ❑ CDC did not accept commercial support for this continuing education activity.

To Ask a Question

❑ Using the Webinar System

- Click the **Q&A** button in the webinar.
- Type your question in the **Q&A** box.
- Submit your question.
- Please note: your question **will not be seen** if submitted via the **chat button**.

❑ For media questions, please contact CDC Media Relations at

- **404-639-3286** or send an email to media@cdc.gov.

❑ If you are a patient, please refer your questions to your healthcare provider.

**At the conclusion of the session,
participants will be able to accomplish
the following:**

- Identify clinical characteristics associated with African tick bite fever, Mediterranean spotted fever, and scrub typhus.
- Describe the available diagnostic tests for African tick bite fever, Mediterranean spotted fever, and scrub typhus.
- Explain the advantages and disadvantages of each diagnostic test and the appropriate time points and specimens for collection.
- Discuss African tick bite fever, Mediterranean spotted fever, and scrub typhus in the context of travel medicine.

Today's First Presenter



Cara Cherry, DVM, MPH, DACVPM

Veterinary Epidemiologist

Rickettsial Zoonoses Branch

Division of Vector-borne Diseases

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention



Today's Second Presenter



Kristina M. Angelo, DO, MPH&TM

Medical Epidemiologist

Travelers' Health Branch (*proposed*)

Division of Global Migration and Quarantine

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention





Travel-associated Rickettsioses Guidance: Pre-travel Counseling, Diagnosis, Treatment, and Reporting

Cara Cherry, DVM, MPH, DACVPM

Veterinary Epidemiologist — Rickettsial Zoonoses Branch

Kristina Angelo, DO, MPH&TM

Medical Epidemiologist — Travelers' Health Branch

Clinician Outreach and Communication Activity (COCA) Call

May 7, 2019

Introduction

Increases in international travel necessitate enhancing tropical disease awareness by health care providers

A person is sitting on a chair in a clinical setting, wearing a white polka-dot dress, pink socks, and brown shoes. A black travel bag is on the floor next to them. The background shows a white cabinet and a chair. The scene is overlaid with a pink text box and a globe graphic.

YOU COVER A LOT OF GROUND.

Mention your international travel plans and history during today's visit.

Your healthcare provider can make recommendations for a healthy trip and quicker diagnosis if you return feeling unwell. Ask for destination-specific tips and updates on disease outbreaks across the globe.

CDC.GOV/TRAVEL 

Numbers of U.S. travelers to international regions have increased steadily during the last decade

- U.S. travelers to Asia
 - 5.8 million in 2017 vs 5.6 million in 2007
- U.S. travelers to Africa
 - 403,151 in 2018 vs. 205,173 in 2007
- Rapid expansion of ecotourism



Tickborne rickettsial pathogens in Asia





Figure 13 from Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier PE, Raoult D, 2013. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev 26: 657-702.

Tsutsugamushi Triangle



Tickborne rickettsial pathogens in North Africa

Tick-Borne Rickettsioses around the World




Figure 10 from Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier PE, Raoult D, 2013. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev 26: 657-702.

Tickborne rickettsial pathogens in sub-Saharan Africa




Figure 11 from Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier PE, Raoult D, 2013. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev 26: 657-702.

African tick bite fever (ATBF)

Rickettsia africae

African tick bite fever

- Caused by infection with the bacterium *Rickettsia africae*
 - Spotted fever group rickettsiosis
- Most commonly diagnosed rickettsial disease among international travelers
- One of the most commonly diagnosed diseases for ill travelers returning from southern Africa
- Disease is primarily associated with travel to Africa
 - *R. africae* has been identified in other parts of the world, such as the Caribbean
- Clusters of cases among families or tourist groups occur commonly

Tickborne rickettsial pathogens in sub-Saharan Africa





Figure 11 from Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier PE, Raoult D, 2013. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev 26: 657-702.

R. africae in the Caribbean

- U.S. Virgin Islands
- Dominica
- Montserrat
- Nevis
- St. Kitts
- St. Lucia



ATBF is transmitted predominately by *Amblyomma hebraeum* or *Amblyomma variegatum* ticks

A. hebraeum
female



A. variegatum
female



A. hebraeum
male



A. variegatum
male



ATBF clinical presentation

- Typically a self-limited disease
- No known deaths attributable to infection with *R. africae*
- Doxycycline is the recommended treatment
 - Patients normally improve 24–48 hours after administration
- Some patients who do not receive appropriate antibiotic therapy may remain febrile for 1-3 weeks
- Rare severe manifestations include reactive arthritis, peripheral neuropathy, or myocarditis

Reported clinical signs among travelers with imported spotted fever group *Rickettsia*



CDC series

- Fever = 69%

Published European case series

81–100%



- Eschar = 55%

53–95%



- Headache = 43%

42–83%



- Rash = 36%

46–62%



- Myalgia = 33%

63–87%

Frequencies of clinical findings described in this evaluation are likely underestimates




PATIENT HISTORY		
BRIEF CLINICAL SUMMARY (Include signs, symptoms, and underlying illnesses if known)		
<input type="text"/>		
STATE OF ILLNESS <input type="checkbox"/> Symptomatic <input type="checkbox"/> Asymptomatic <input type="checkbox"/> Acute <input type="checkbox"/> Chronic <input type="checkbox"/> Convalescent <input type="checkbox"/> Recovered	TYPE OF INFECTION <input type="checkbox"/> Upper respiratory <input type="checkbox"/> Lower respiratory <input type="checkbox"/> Cardiovascular <input type="checkbox"/> Gastrointestinal <input type="checkbox"/> Genital <input type="checkbox"/> Urinary tract <input type="checkbox"/> Other, specify <input type="text"/>	THERAPEUTIC AGENT(S) DURING ILLNESS Agent Start date End date 1. <input type="text"/> <input type="text"/> <input type="text"/> 2. <input type="text"/> <input type="text"/> <input type="text"/> 3. <input type="text"/> <input type="text"/> <input type="text"/>
EPIDEMIOLOGICAL DATA		
EXTENT <input type="checkbox"/> Isolated case <input type="checkbox"/> Carrier <input type="checkbox"/> Contact <input type="checkbox"/> Outbreak <input type="text"/> <input type="checkbox"/> Family <input type="checkbox"/> Community <input type="checkbox"/> Healthcare-associated <input type="checkbox"/> Epidemic	TRAVEL HISTORY Travel: <input type="text"/> Dates of Travel: <input type="text"/> to <input type="text"/> Travel: Foreign (Countries) <input type="text"/> <input type="text"/> <input type="text"/> Foreign Residence (Country) <input type="text"/> Travel: United States (States) <input type="text"/> <input type="text"/> <input type="text"/> United States Residence (State) <input type="text"/>	
Note: Additional states or countries of residence or travel should be entered in the Brief Clinical Summary field.		
EXPOSURE HISTORY Exposure: <input type="text"/> Date of Exposure: <input type="text"/> <input type="checkbox"/> Animal Type of Exposure: <input type="text"/> Common name: <input type="text"/> Scientific name: <input type="text"/> <input type="checkbox"/> Arthropod Type of Exposure: <input type="text"/> Common name: <input type="text"/> Scientific name: <input type="text"/>	RELEVANT IMMUNIZATION HISTORY Immunization(s) Date received 1. <input type="text"/> <input type="text"/> 2. <input type="text"/> <input type="text"/> 3. <input type="text"/> <input type="text"/> 4. <input type="text"/> <input type="text"/>	

Eschars are an important clinical feature of ATBF

- Also occur in SFGR caused by other *Rickettsia* species endemic to sub-Saharan Africa
 - *R. conorii*,
 - *R. aeschlimannii*,
 - *R. sibirica mongolitimonae*
 - *R. monacensis*

What is an eschar?



- A lesion that occurs at the site of a tick bite
- Forms within a few days (median 5 days) after the bite
- May take several weeks to heal completely

Images A and B courtesy of Charles Thurston M.D. and Lester Libow M.D., TX;
Images C and D courtesy of Sherif Zaki, MD, PhD, CDC.

Early eschars can look like a small vesicle or like an erythematous plaque



Eschar will develop into a central, 0.5–3.0 cm ulcer covered by a brown-black crust and surrounded by an annular red halo



The healed lesion typically appears as a small depressed scar



Mediterranean spotted fever (MSF)

Rickettsia conorii conorii

Rickettsia conorii complex

- *R. conorii conorii*
 - Mediterranean spotted fever
 - Mediterranean basin, Africa, Croatia, Slovenia
- *R. conorii israelensis*
 - Israeli spotted fever
 - Israel, Portugal, Sicily
- *R. conorii caspia*
 - Astrakhan spotted fever
 - Astrakhan region of Russia, Chad, Kosovo
- *R. conorii indica*
 - Indian tick typhus
 - India, Pakistan

Mediterranean spotted fever

- Caused by infection with the bacterium *Rickettsia conorii conorii*
 - Spotted fever group rickettsiosis
- AKA boutonneuse fever
- Sporadic cases
- More severe than ATBF
- Cases mainly occur in warm months (July–September)

MSF is endemic in the Mediterranean basin, northern Africa, and southern Europe



MSF is transmitted by *Rhipicephalus sanguineus*



Michael L. Levin, CDC

MSF clinical presentation

- Abrupt onset of high fever with headache, chills, and myalgia
- Eschar present in 60–86% of patients
 - Rare to see multiple eschars
- Rash appears 2–3 days after fever
 - Develops in 96–99% of patients

Severe forms of MSF

- Neurological manifestations from meningoencephalitis
- Deep vein thrombosis
- Multiorgan involvement
 - Kidneys, lungs, GI tract, liver, pancreas, heart, spleen
- Purpuric rash

Risk factors for severe manifestations of MSF

- Advanced age
- Immunocompromised
- Diabetes mellitus
- Cardiac insufficiency
- Alcoholism
- G6PD deficiency


Scrub typhus

Orientia tsutsugamushi

Scrub typhus

- Caused by infection with the bacterium *Orientia tsutsugamushi*
 - Over 70 known strains
- Rural disease prevalent in much of the world
 - Common in Southeast Asia and the Pacific
- In 1999, WHO reported that “Scrub typhus is probably one of the most underdiagnosed and underreported febrile illnesses requiring hospitalization in the region”
- Second most common rickettsial disease in international travelers

Scrub typhus is emerging in areas outside the tsutsugamushi triangle



- Triangle extends from far eastern Russia to northern Australia to Afghanistan
- Newly discovered autochthonous cases in:
 - Chile
 - Dubai*
 - Cameroon
 - Kenya
 - Republic of Congo
 - Djibouti
 - Tanzania

*=isolation of a novel species *O. chuto*

Chigger environments

- Occur in overgrown brushy or grassy areas
 - Especially where small rodents are abundant
- Prefer shady areas with plenty of moisture



Scrub typhus clinical presentation

- Ranges from mild to fatal illness.
- Early clinical manifestations
 - Eschar(s) — wide range of occurrence (1–97%)
 - Regional lymphadenopathy
- 10–14 days after exposure
 - Fever, headache, myalgia, generalized lymphadenopathy, cough, gastrointestinal symptoms, rash
- Varying case fatality rates

Severe manifestations of scrub typhus

- Acute respiratory distress
- Pneumonitis
- Meningoencephalitis
- Gastrointestinal bleeding
- Acute renal failure
- Hypotensive or septic shock
- Coagulopathy
- Myocarditis or pericarditis

Treatment

Doxycycline is the treatment of choice for all age groups

- Appropriate antibiotic therapy should not be delayed

Recommended by:

American Academy of Pediatrics

Centers for Disease Control and Prevention

Doxycycline
saves lives!

A good reason to smile:
Doxycycline is the **#1 recommended treatment** for suspected rickettsial infections in patients of all ages.

New research shows **NO** evidence of tooth staining when used in short courses.



Click to learn more.

Outdated perceptions: Doxycycline in pediatric patients

- In 1970, FDA placed a warning label on all tetracycline-related medications, including doxycycline
 - Believed to be associated with enamel hypoplasia and tooth discoloration



Doxycycline and tooth staining, Arizona

- 2013 Study examined the erupted teeth of 58 children who received doxycycline before 8 years old
 - NO staining or hypoplasia, even with multiple short courses
 - NO significant difference in objective tooth shade between exposed and unexposed children
- CDC and the American Academy of Pediatrics (AAP) recommend doxycycline as **first line** treatment for suspected RMSF in children.

Doxycycline dosing

- Adult or child ≥ 45 kg = 100 mg twice daily
- Child < 45 kg: 2.2 mg/kg twice daily
- Pregnant adult or tetracycline allergy: consult infectious diseases specialist, in severe cases doxycycline may be warranted
- Duration of treatment: 5-7 days (or 3 days past defervescence)

Doxycycline
saves lives!



Use it to treat suspected rickettsial infections in patients of all ages.


New research shows NO evidence of pediatric dental staining when used in short courses.

[Click to learn more.](#)



Diagnosis

Diagnosing ATBF, MSF, and Scrub typhus




- Few (no?) commercial U.S. laboratories provide specific testing
 - Cross reactivity with other spotted fevers
- CDC's Rickettsial Zoonoses Branch Diagnostic Laboratory
 - IgG IFA serology for *R. africae*, *R. conorii*, *O. tsutsugamushi*
 - PCR for pan-*Rickettsia* or *Orientia* on fresh tissue biopsies (rash, eschar, organ), eschar swabs, and whole blood
- CDC's Infectious Diseases Pathology Branch
 - Immunohistochemistry (IHC) on fixed skin or organ biopsies

How to confirm disease

- Serology (serum)
 - Four-fold change in IgG-specific antibody titer by indirect immunofluorescence antibody (IFA) assay in paired serum samples.
 - Acute: first two weeks or while symptomatic
 - Convalescent: 4–6 weeks after acute draw (depending on pathogen)
- Molecular diagnostics (whole blood)
 - Sensitivity can be low during early acute illness

Estimated utility of diagnostic tests over time



The reported median time to IgG seroconversion to *R. africae* is 28 days after onset of symptoms




FIG. 2. (A) Cumulative percentage of IgM seroconversion against *R. conorii* (gray curve) and *R. africae* (black curve) in patients with African tick-bite fever. (B) Cumulative percentage of IgG seroconversion against *R. conorii* (gray curve) and *R. africae* (black curve) in patients with African tick-bite fever.

From Fournier PE, Jensenius M, Laferl H, Vene S, Raoult D, 2002. Kinetics of antibody responses in *Rickettsia africae* and *Rickettsia conorii* infections. Clin Diag Lab Immunol 9: 324-328.

PCR of eschar swabs or biopsies provides a confirmed diagnosis in the early stage of the disease

1



Cleanse the eschar with a standard disinfectant solution.
Use sterile saline to remove remaining disinfectant.


2

Use sterile tweezers to lift the scab partially or completely.
It is not necessary to remove the scab entirely if it is firmly attached. If removed, place the scab into an empty, sterile specimen container.



PCR of eschar swabs or biopsies provides a confirmed diagnosis in the early stage of the disease


3



Use a dry, sterile cotton swab to sample the ulcerated area. Rotate the swab vigorously on ulcerated area while applying steady, gentle pressure.

4

Place the swab in a sterile specimen container. Swab can be placed in the same sterile specimen container as the scab.



5

Ship specimen immediately overnight on cold packs or freeze and ship on dry ice.

Key Takeaways

Travel-associated rickettsial disease summary

Disease	Pathogen	Geography	Vector	Eschars
African tick bite fever	<i>Rickettsia africae</i>	Sub-Saharan Africa, West Indies	<i>Ambylomma</i> ticks	Sometimes multiple
Mediterranean spotted fever	<i>Rickettsia conorii conorii</i>	Mediterranean basin, northern Africa	<i>Rhicephalus</i> ticks	Usually single
Scrub typhus	<i>Orientia tsutsugamushi</i>	Southeast Asia and the Pacific	Chiggers	Presence varies greatly

Consider imported rickettsial diseases

- When evaluating patients for a febrile illness with eschar and compatible foreign travel history
- Diagnostic sampling techniques should include:
 - Two serum samples, one collected during the acute illness and a second sample collected at 4–6 weeks after symptom onset
 - PCR testing of eschar biopsies or swabs and whole blood, when available
- Appropriate antibiotic therapy should not be delayed
 - Doxycycline (100 mg twice daily) is the recommended dose for adults;
 - 2.2 mg/kg body weight twice daily is the recommended dose for children under 100 lbs.

Image Credits

- Figure 10 and 11 from Parola P, Paddock CD, Socolovschi C, Labruna MB, Mediannikov O, Kernif T, Abdad MY, Stenos J, Bitam I, Fournier PE, Raoult D, 2013. Update on tick-borne rickettsioses around the world: a geographic approach. Clin Microbiol Rev 26: 657-702.
- James Gathany (CDC) for the photographic images of ticks
- Charles Thurston and Lester Libow (Aurora Diagnostics) for eschar photos
- Sherif Zaki (CDC) for eschar histopath images
- Meredith Boyter Newlove (CDC) for eschar stages and how to collect eschar illustrations
- Figure 2 from Fournier PE, Jensenius M, Laferl H, Vene S, Raoult D, 2002. Kinetics of antibody responses in Rickettsia africae and Rickettsia conorii infections. Clin Diag Lab Immunol 9: 324-328.
- Stock photos from pexels.com
- Icons from the Noun Project
<https://thenounproject.com/>
 - Rash by Pierce Meehan
 - Headache by Artem Kovyazin
 - Rash by Priyanka
 - Knee pain by Gan Khoon Lay

Prevention of Rickettsioses in the Context of Travel Medicine

What is a Pre-travel Consultation?

- Visit with a healthcare provider **at least 4 weeks before travel**
 - Travel medicine specialist
 - Primary care physician
- Typically does NOT include a physical exam



Opportunities at the Pre-travel Consultation

- Receive personalized travel advice



Opportunities at the Pre-travel Consultation

- Receive personalized travel advice
- Depart with both verbal and written information for reference



VACCINE INFORMATION STATEMENT

Meningococcal ACWY Vaccines—MenACWY and MPSV4: What You Need to Know

1 Why get vaccinated?

Meningococcal disease is a serious illness caused by a type of bacteria called *Neisseria meningitidis*. It can lead to meningitis (infection of the lining of the brain and spinal cord) and infections of the blood. Meningococcal disease often occurs without warning—most among people who are otherwise healthy.

Meningococcal disease can spread from person to person through close contact (coughing or kissing or lengthy contact), especially among people living in the same household.

There are at least 12 types of *N. meningitidis*, called “serogroups.” Serogroups A, B, C, W, and Y cause most meningococcal diseases.

Anyone can get meningococcal disease but certain people are at increased risk, including:

- Infants younger than one year old
- Adolescents and young adults 16 through 23 years old
- People with certain medical conditions that affect the immune system
- Microbiologists who routinely work with isolates of *N. meningitidis*
- People at risk because of an outbreak in their community

Even when it is detected, meningococcal disease kills 10 to 13 out of every 100 people out of 100. And of those who survive, about 10 to 20 out of every 100 will suffer disabilities such as hearing loss, brain damage, kidney damage, amputations, serious eye vision problems, or severe scars from skin grafts.

Meningococcal ACWY vaccines can help prevent meningococcal disease caused by serogroups A, C, W, and Y. A different meningococcal vaccine is available to help protect against serogroup B.

2 Meningococcal ACWY Vaccines

There are two kinds of meningococcal vaccines licensed by the Food and Drug Administration (FDA) for protection against serogroups A, C, W, and Y: meningococcal conjugate vaccine (MenACWY) and meningococcal polysaccharide vaccine (MPSV4).

Two doses of MenACWY are routinely recommended for adolescents 11 through 14 years old: the first dose at 11 or 12 years old, with a booster dose at age 16. Young adolescents, including those with HIV, should get additional doses. Ask your health care provider for more information.

In addition to routine vaccination for adolescents, MenACWY vaccine is also recommended for certain groups of people:

- People at risk because of a serogroup A, C, W, or Y meningococcal disease outbreak
- Anyone whose spleen is damaged or has been removed
- Anyone with a rare immune system condition called “persistent complement component deficiency.”
- Anyone taking a drug called eculizumab (also called “Soliris”).
- Microbiologists who routinely work with isolates of *N. meningitidis*
- Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as parts of Africa
- College freshmen living in dormitories
- U.S. military recruits

Children between 7 and 23 months old, and people with certain medical conditions need multiple doses for adequate protection. Ask your health care provider about the number and timing of doses, and the need for booster doses.

MenACWY is the preferred vaccine for people in these groups who are 2 months through 55 years old, have received MenACWY previously, or anticipate requiring multiple doses.

MPSV4 is recommended for adults older than 16 who anticipate requiring only a single dose (travelers, or during community outbreaks).

CDC U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Opportunities at the Pre-travel Consultation

- Receive personalized travel advice
- Depart with both verbal and written information for reference
- Get vaccinations and medications



VACCINE INFORMATION STATEMENT

Meningococcal ACWY Vaccines—MenACWY and MPSV4: What You Need to Know

1 Why get vaccinated?

Meningococcal disease is a serious illness caused by a type of bacteria called *Neisseria meningitidis*. It can lead to meningitis (inflammation of the lining of the brain and spinal cord) and infections of the blood. Meningococcal disease often occurs without warning—most among people who are otherwise healthy.

Meningococcal disease can spread from person to person through close contact (coughing or sneezing) or through contact, especially among people living in the same household.

There are at least 11 types of *N. meningitidis*, called “serotypes.” Serotypes A, B, C, W, and Y cause most meningococcal diseases.

Anyone can get meningococcal disease but certain people are at increased risk, including:

- Infants younger than one year old
- Adolescents and young adults 16 through 23 years old
- People with certain medical conditions that affect the immune system
- Microbiologists who routinely work with isolates of *N. meningitidis*
- People at risk because of an outbreak in their community

Even when it is treated, meningococcal disease kills 10 to 11 million people out of 100. And of those who survive, about 10 to 20 out of every 100 will suffer disabilities such as hearing loss, brain damage, kidney damage, paraplegia, nervous system problems, or severe scars from skin grafts.

Meningococcal ACWY vaccines can help prevent meningococcal disease caused by serotypes A, C, W, and Y. A different meningococcal vaccine is available to help protect against serotype B.

2 Meningococcal ACWY Vaccines

There are two kinds of meningococcal vaccines licensed by the Food and Drug Administration (FDA) for protection against serotypes A, C, W, and Y: meningococcal conjugate vaccine (MenACWY) and meningococcal polysaccharide vaccine (MPSV4).

Two doses of MenACWY are routinely recommended for adolescents 11 through 14 years old: the first dose at 11 to 12 years old, with a booster dose at age 16. Some adolescents, including those with HIV, should get additional doses. Ask your health care provider for more information.

In addition to routine vaccination for adolescents, MenACWY vaccine is also recommended for certain groups of people:

- People at risk because of a serotype A, C, W, or Y meningococcal disease outbreak
- Anyone whose spleen is damaged or has been removed
- Anyone with a rare immune system condition called “persistent complement component deficiency”
- Anyone taking a drug called sulfamonomethoxime (also called “Solis®”)
- Microbiologists who routinely work with isolates of *N. meningitidis*
- Anyone traveling to, or living in, a part of the world where meningococcal disease is common, such as parts of Africa
- College freshmen living in dormitories
- U.S. military recruits


Children between 2 and 23 months old, and people with certain medical conditions need multiple doses for adequate protection. Ask your health care provider about the number and timing of doses, and the need for booster doses.

MenACWY is the preferred vaccine for people in these groups who are 1 month through 33 years old, have received MenACWY previously, or anticipate requiring multiple doses.

MPSV4 is recommended for adults older than 55 who anticipate requiring only a single dose (travelers, or during community outbreaks).



Three Key Components of the Pre-travel Consultation



Risk Assessment

Key Information to Collect to Perform a Travel Risk Assessment

- Past medical history
- Special conditions
- Immunization history
- Trip details

Past Medical History

- Age
 - Sex
 - Underlying medical conditions
 - Medications
 - Allergies
- 

Consideration of Special Conditions

- Reproductive health
 - Pregnancy
 - Breastfeeding
 - Plans to become pregnant
- Disability / Handicap
- Immunocompromise
- History of Guillain-Barré syndrome
- Recent surgery or medical event



Immunization History

- Routine vaccines
- Travel vaccines



Trip Details: Itinerary and Timing

- Itinerary
 - Country (ies)
 - Layovers
 - Urban vs rural



Trip Details: Itinerary and Timing

- Itinerary
 - Country (ies)
 - Layovers
 - Urban vs rural
- Timing
 - Duration
 - Season at destination
 - Time to departure



Trip Details: Reasons for Travel

- Tourism
- Business
- Research
- Education
- Adventure
- Visiting friends and relatives
- Volunteer, missionary, or aid work
- Seeking health care (medical tourism)
- Pilgrimage
- Adoption

Trip Details: Travel Style

- Tour vs self-planned
 - Solo vs group
 - Eating habits
 - Hygiene standards
 - Modes of transportation
 - Accommodations
- 

Trip Details: Special Activities

- Extreme sports (sky diving, cliff jumping, etc.)
- High altitude
- Safari
- Disaster relief
- Providing or receiving medical care
- Cruise ship
- Fresh water exposure (rafting, wading, etc.)
- Animal interaction
- Camping
- Hiking



Trip Details: Special Activities

- Extreme sports (sky diving, cliff jumping, etc.)
- High altitude
- Safari
- Disaster relief
- Providing or receiving medical care
- Cruise ship
- Fresh water exposure (rafting, wading, etc.)
- Animal interaction
- Camping
- Hiking

Counseling and Education: Rickettsioses

Prevention: Arthropod and Animal Avoidance

- Minimize exposure to:
 - Biting arthropods
 - Animals that serve as reservoirs
- Be aware of peak exposure times and places for insects/arthropods

Minimizing Exposure to Biting Arthropods

- Cover exposed skin by wearing long-sleeved shirts, long pants, and hats
 - Tuck in shirts
 - Tuck pants into socks
 - Wear closed-toed shoes
- Treat clothing and gear with 0.5% permethrin
- Avoid wooded areas with high grass, brush, and leaves
- Walk in the center of hiking trails
- Use repellents and insecticides




Prevention: Personal Protective Measures

- Wear appropriate, protective clothing (long sleeves and long pants)

Prevention: Personal Protective Measures


- Wear appropriate, protective clothing (long sleeves and long pants)
- Perform daily self-examination
 - Bathe or shower soon after coming indoors
 - Use a hand-held or full length mirror
 - Remove ticks properly

Self-Examination



Tick Removal

- Use tweezers to grasp the tick as close to the skin's surface as possible.
- Pull upward with steady, even pressure.
- After removing the tick, thoroughly clean the bite area and your hands with rubbing alcohol or soap and water
- Dispose of a live tick by putting it in alcohol, placing it in a sealed bag/container, wrapping it tightly in tape, or flushing it down the toilet



Prevention: Personal Protective Measures, continued

- Sleep under insecticide-treated bed nets

Prevention: Personal Protective Measures, continued

- Sleep under insecticide-treated bed nets
- Check pets and belongings

Prevention: Personal Protective Measures

- Sleep under insecticide-treated bed nets
- Check pets and belongings
- Use repellents
 - DEET (at least 20%)
 - Picaridin
 - Oil of lemon eucalyptus (OLE)
 - IR3535
 - 2-undecanone
 - Permethrin

Repellent Efficacy

- Varies among products
- Impacted by:
 - Temperature
 - Level of activity
 - Amount of perspiration
 - Exposure to water
- Apply according to label instructions for maximum effect

Repellent Precautions

- Apply only to exposed skin or clothing
- Never use on cut or irritated skin
- Do not spray directly to the face
- Avoid contact with the eyes and mouth
- Wash hands after application
- Avoid oversaturation
- Wash repellent-treated skin with soap and water

Application of Sunscreen and Repellents



Travel Kit

- Medications
 - Prescription
 - Over-the counter
 - Antacid
 - Antihistamine
 - Anti-diarrheals
 - Decongestant, cold medicine, cough suppressant
 - Pain relief (aspirin, ibuprofen, etc.)
 - Antibiotic/antifungal/hydrocortisone creams
- Bandages
- Tweezers
- Insect repellent, sunscreen
- Thermometer
- Hand sanitizer

Vaccines

Prevention: Vaccines and Pharmaceuticals

- No vaccine is available to prevent rickettsioses
- Antibiotics are not recommended for prophylaxis

Evaluation of a Traveler with Suspected Rickettsioses

Consider the Following During a Post-travel Evaluation

- Travel itinerary and activities
- Timing of the illness related to travel
- Comorbidities



Consider the Following During a Post-travel Evaluation

- Travel itinerary and activities
- Timing of the illness related to travel
- Comorbidities



African Tick Bite Fever

- Travel itinerary and activities
 - November through April
 - Sub-Saharan Africa, West Indies
 - Camping, hiking, hunting
 - Spending time in wooded, brushy, or grassy areas



African Tick Bite Fever

- Timing of the illness related to travel
 - Within 2 weeks of a tick bite
 - First symptoms is usually an eschar
 - Fever, headache, myalgia, and rash



Scrub Typhus

- Travel itinerary and activities
 - Rural areas of Southeast Asia, Indonesia, China, Japan, India, Sri Lanka, western Pacific islands, or northern Australia
 - Camping, hiking, rafting
 - High grass and brush



Scrub Typhus

- Timing of the illness related to travel
 - Within 10 days of a chigger bite
 - Fever, headache, myalgia, eschar, and rash



Mediterranean Spotted Fever

- Travel itinerary and activities
 - Summer months
 - Southern Europe, southern and western Asia, Africa, and India



Mediterranean Spotted Fever

- Timing of the illness related to travel
 - Within 14 days of a tick bite
 - Fever, headache, myalgia, eschar and rash



Management of Rickettsioses

- Ask about international travel
- Check with the local or state health department about reporting requirements
 - Spotted fever group rickettsioses are nationally notifiable diseases
- Admit patients to inpatient care if their presentation is severe
- Consult with an infectious disease physician

Resources

CDC Travelers' Health Website

Travelers' Health

- Home
- Destinations
- Travel Notices
- Yellow Fever Information
- Zika Travel Information +
- Find a Clinic +
- Disease Directory
- Resources +
- Resources for Travelers +
- Resources For Clinicians +
- Resources for the Travel Industry
- Yellow Book +
- Partners +
- Mobile Apps
- RSS Feeds

CDC



VACCINES. MEDICINES. ADVICE.

In the News: Get the latest updates on [yellow fever](#) and [Zika virus](#).



For Travelers



Where are you going?

-- Select One -- 

For Clinicians



Traveler destination

-- Select One -- 

Traveler's health website

Travelers' Health

Home

Destinations

Travel Notices

Yellow Fever Information

Zika Travel Information



Find a Clinic



Disease Directory (41)



African Tick-Bite Fever

Resources



Resources for Travelers



Resources For Clinicians



Resources for the Travel Industry

[CDC](#) > [Home](#) > [Disease Directory \(41\)](#)

African Tick-Bite Fever



What is African tick-bite fever?

African tick-bite fever is a bacterial infection that is spread through the bite of infected ticks. Symptoms usually appear within 2 weeks after a tick bite and often include fever, headache, muscle soreness, and a rash. At the site of the tick bite will be a red skin sore with a dark center.

Who is at risk?

Travelers to sub-Saharan Africa and the West Indies are at risk of infection. You may be at higher risk for African tick-bite fever if your travel plans include outdoor activities such as camping, hiking, and game hunting in wooded, brushy, or grassy areas. Ticks that are infected with tick-bite fever are usually most active from November through April.


What can travelers do to prevent African tick-bite fever?

On This Page

- [What is African tick-bite fever?](#)
- [Who is at risk?](#)
- [What can travelers do to prevent African tick-bite fever?](#)
- [Information for travelers](#)
- [Clinician Information](#)

CDC Yellow Book

- Current travel health guidelines
- Vaccine recommendations
- Destination-specific advice
- Maps, tables, and charts



For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.



Questions?



To Ask a Question

- **Using the Webinar System**
 - Click the **Q&A** button in the webinar
 - Type your question in the **Q&A** box
 - Submit your question in the **Q&A** box

- **CDC Media: media@cdc.gov or 404-639-3286**

- **Patients, please refer your questions to your healthcare provider.**

Today's webinar will be archived

When: A few days after the live call

What: All call recordings (audio, webinar, and transcript)

Where: On the COCA Call webpage

<https://emergency.cdc.gov/coca>

Continuing Education for this COCA Call

All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and AAVSB/RACE) for COCA Calls are issued online through the [CDC Training & Continuing Education Online system](http://www.cdc.gov/TCEOnline/) (<http://www.cdc.gov/TCEOnline/>).

Those who participated in today's COCA Call and who wish to receive continuing education should complete the online evaluation by **June 10, 2019**, with the course code **WC2922**.

Those who will participate in the on demand activity and wish to receive continuing education should complete the online evaluation between **June 10, 2019**, and **June 10, 2021**, will use course code **WD2922**.

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE's obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

Next COCA Call

“Most Measles Cases in 25 Years: Is the End of Measles Elimination in the United States?”

Tuesday, May 21, 2019

2:00 P.M. ET

COCA Products & Services

		COCA Call
		CDC Clinician Outreach and Communication Activity

Promotes COCA Calls and contains all information subscribers need to participate in COCA Calls. COCA Calls are done as needed.

		COCA Learn
		CDC Clinician Outreach and Communication Activity

Monthly email that provides information on CDC training opportunities, conference and training resources located on the COCA website, the COCA Partner Spotlight, and the Clinician Corner.

		Clinical Action
		CDC Clinician Outreach and Communication Activity

Provides comprehensive CDC guidance so clinicians can easily follow recommendations.

COCA Products & Services



Monthly email that provides new CDC & COCA resources for clinicians from the past month and additional information important during public health emergencies and disasters.



Informs clinicians of new CDC resources and guidance related to emergency preparedness and response. This email is sent as soon as possible after CDC publishes new content.




CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories.

Join COCA's Mailing List!

Receive information
about:

- Upcoming COCA Calls
- Health Alert Network notices
- CDC public health activations
- Emerging health threats
- Emergency preparedness and response conferences and training opportunities



<http://emergency.cdc.gov/coca>

Join Us on Facebook!



COCA

CDC Clinician Outreach and Communication Activity - COCA ✓
@CDCClinicianOutreachAndCommunicationActivity

Home
About
Posts
Photos
Events
Community
Create a Page

Liked Following Share ... Sign Up

Status
Write something on this Page...

Posts
COCA CDC Clinician Outreach and Communication Activity - COCA shared their event.
October 31 at 1:18pm · 🌐
Clinicians, you can earn FREE CE with this COCA Call! Join us for this COCA Call November 7, 2017 at 2:00PM.

Government Organization in Atlanta, Georgia
Community See All
21,420 people like this
21,217 people follow this
About See All
1600 Clifton Rd NE
Atlanta, Georgia 30333

Thank you for joining!



**Centers for Disease Control and Prevention
Atlanta, Georgia**

<http://emergency.cdc.gov/coca>